CureVac drops COVID-19 vaccine candidate; shifts focus to second-generation mRNA program

CureVac is withdrawing its first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review: instead it is re-allocating its efforts to its second-generation vaccine program with GSK. ‘The goal has not changed, but the requirements to effectively address the virus and emerging variants have changed,’ says the company.